Key Insights

Highlights

Success Rate

77% trial completion

Published Results

48 trials with published results (17%)

Research Maturity

135 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

14.5%

41 terminated out of 282 trials

Success Rate

76.7%

-9.8% vs benchmark

Late-Stage Pipeline

10%

29 trials in Phase 3/4

Results Transparency

36%

48 of 135 completed with results

Key Signals

48 with results77% success41 terminated

Data Visualizations

Phase Distribution

233Total
Not Applicable (82)
Early P 1 (3)
P 1 (46)
P 2 (73)
P 3 (21)
P 4 (8)

Trial Status

Completed135
Unknown43
Terminated41
Recruiting30
Withdrawn15
Active Not Recruiting11

Trial Success Rate

76.7%

Benchmark: 86.5%

Based on 135 completed trials

Clinical Trials (282)

Showing 20 of 20 trials
NCT05187091Phase 3RecruitingPrimary

The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas

NCT05308732Phase 1Active Not RecruitingPrimary

Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy

NCT03429036Recruiting

Biospecimen Procurement for Head and Neck Disorders

NCT07556367Not ApplicableRecruiting

Post-Radiation Oral Health in Underserved Head and Neck Cancer Patients

NCT05511714Unknown

Expanded Access [11C] Methionine PET Imaging

NCT03818061Phase 2CompletedPrimary

Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

NCT05432297Not ApplicableRecruitingPrimary

Preventive Physical Activity Intervention in Head and Neck Cancer

NCT04612075RecruitingPrimary

The EMINENCE Study - PET/MR Imaging of Head Neck Cancer

NCT00200486RecruitingPrimary

Molecular and Genomic Profiling of Head and Neck Tumors

NCT05420948Phase 2Suspended

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

NCT06110195Phase 1Terminated

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

NCT05418842Not ApplicableCompletedPrimary

Exercise Prehabilitation in Patients With Head and Neck Squamous-cell Carcinoma: The FIT4TREAT Trial

NCT07491536Not ApplicableRecruiting

Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis

NCT06910566Active Not Recruiting

Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy

NCT06003231Phase 2Active Not Recruiting

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT02568267Phase 2Active Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT04222972Phase 3Terminated

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04075305Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT05544136Phase 2Recruiting

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

NCT05647122Phase 1Recruiting

First in Human Study of AZD9592 in Solid Tumors

Scroll to load more

Research Network

Activity Timeline